Drugs / AMG 337
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01253707 | Dec 2010 → Oct 2015 | cancer | Amgen | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT02344810 | Mar 2015 | diffuse gastric adenocarcinoma, esophageal adenocarcinoma, gastric intestinal type adenocarcinoma, gastroesophageal junction adenocarcinoma | Eastern Cooperative Oncology Group | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT02096666 | Apr 2014 → Nov 2015 | gastric neoplasm | Amgen | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT03132155 | Aug 2018 → Aug 2021 | clear cell sarcoma | NantPharma, LLC | Terminated | No outcome recorded |
| Phase 2 | NCT03147976 | May 2018 → Aug 2019 | cancer | NantPharma, LLC | Withdrawn | No outcome recorded |
| Phase 2 | NCT02016534 | Feb 2014 → Oct 2016 | gastric neoplasm | Amgen | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AMG 337 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03132155 ↗ |
| Action | Inhibit | “AMG 337 is a small molecule inhibitor of c-Met” NCT01253707 ↗ |
| Modality | Small molecule | “AMG 337 is a small molecule inhibitor of c-Met” NCT01253707 ↗ |
| Route | Oral | “AMG 337 300mg orally daily.” NCT02016534 ↗ |
| Target | MET | “C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil” NCT02344810 ↗ |